CDH17 and colorectal adenocarcinoma: Furthermore, the lack of CDH17 expression by healthy stomach tissue similarly suggests that the probe could be valuable in patients with stomach and gastric cancer, but higher levels of expression in the colon may portend challenges in the context of colorectal adenocarcinoma [29, 30].